RxDoctor Payments Data

Darryl Prince, MD

Neurology · Waukesha, WINPI 1851300362

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $16,275 of the $18,937 with a category attached, or 85.9%. Biohaven Pharmaceuticals, Inc. accounts for 65.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $10,642 and has fallen 98.3% since, to $182 in 2025. Among neurology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,937in general payments, 2019–2025

Across 44 payments — averaging $430.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$12K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • TG Therapeutics, Inc.$546
  • Alnylam Pharmaceuticals Inc.$255
  • Genentech USA, Inc.$230
  • Biogen$150
  • plus $661 from 12 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$16,27586%
  • Food & beverage$2,47713%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,937 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Wisconsin.

See all neurology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$162,568
Medicare patients
409
Services billed
15,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant49$63,708
KeppraLevetiracetam11$25,134
Nurtec OdtRimegepant Sulfate23$24,829
LamictalLamotrigine11$18,336
RytaryCarbidopa/Levodopa14$17,853
Emgality PenGalcanezumab-Gnlm16$11,524
Memantine Hcl300$9,397
Levetiracetam219$7,277
Divalproex Sodium53$6,299
SavellaMilnacipran Hcl11$5,203
Oxcarbazepine65$4,766
Fentanyl20$4,623
TegretolCarbamazepine12$4,464
Carbidopa-LevodopaCarbidopa/Levodopa213$4,418
Lamotrigine155$3,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Savella$13$68,91160 claims
PfizerNurtec Odt$25$24,82923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 neurology providers in Wisconsin.

Other neurology in Waukesha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →